BioCentury | Apr 13, 2015
Clinical News

Mucogard: Phase II started

...evaluate oral MuGard in about 66 women with hormone receptor-positive breast cancer receiving Afinitor everolimus. MuGard...
...treat and prevent oral mucositis. Norgine has exclusive rights from PlasmaTech to develop and commercialize MuGard...
...Norgine B.V. , Amsterdam, the Netherlands PlasmaTech Biopharmaceuticals Inc. (NASDAQ:PTBI), Dallas, Texas Product: Mucogard ( MuGard...
BioCentury | Apr 13, 2015
Clinical News

Mucogard regulatory update

...approved a regulatory application from partner Hanmi Pharmaceutical Co. Ltd. (KOSDAQ:128940, Seoul, South Korea) for Mucogard...
...exclusive, commercialization rights to the product under a 2014 deal (see BioCentury, March 17, 2014). MuGard...
...Norgine B.V. , Amsterdam, the Netherlands PlasmaTech Biopharmaceuticals Inc. (NASDAQ:PTBI), Dallas, Texas Product: Mucogard ( MuGard...
BioCentury | Nov 24, 2014
Company News

Access Pharmaceuticals, Norgine deal

...Zealand to an August deal granting Norgine an exclusive license to commercialize, develop and manufacture MuGard...
...terms are identical to the August deal. In August, Norgine had said it anticipated launching MuGard...
BioCentury | Sep 8, 2014
Company News

Access Pharmaceuticals, Norgine deal

...Access granted Norgine exclusive rights to develop and commercialize Access' MuGard for oral mucositis in the...
...clearance to the product in December 2006. Access reported $1.5 million in U.S. sales of MuGard...
BioCentury | Mar 17, 2014
Company News

Access Pharmaceuticals, Hanmi Pharmaceutical sales and marketing update

...Access granted Hanmi exclusive rights to commercialize MuGard in South Korea. Access will receive an undisclosed...
BioCentury | Mar 3, 2014
Clinical News

MuGard: Phase IV data

...cancer patients receiving chemoradiation therapy in a double-blind, U.S. Phase IV trial showed that oral MuGard...
...primary endpoint, from baseline to last day of chemoradiation therapy vs. sham control (p=0.034). Additionally, MuGard...
...The trial enrolled 120 patients to receive 5 mL aqueous control rinse or 5 mL MuGard...
BioCentury | Jun 17, 2013
Company News

Access Pharmaceuticals, AMAG Pharmaceuticals sales and marketing update

...AMAG licensed exclusive, U.S. commercialization rights to MuGard mucoadhesive oral rinse from Access for an upfront...
...for a tiered, double-digit royalty on net sales of MuGard. AMAG also will purchase existing MuGard...
...Leerink Swann was financial advisor to AMAG. The companies could not be reached for details. MuGard...
BioCentury | Apr 30, 2012
Clinical News

MuGard: Interim Phase IV data

...showed that oral MuGard significantly reduced mouth and throat soreness vs. an aqueous control rinse. MuGard...
...5 mL MuGard rinse every 3 hours while awake for up to 6 times daily. MuGard...
...in the U.S. to treat and prevent OM. Access Pharmaceuticals Inc. (OTCBB:ACCP), Dallas, Texas Product: MuGard...
BioCentury | Mar 5, 2012
Clinical News

MuGard regulatory update

...for MuGard mucoadhesive oral rinse to treat oral mucositis (OM) in cancer patients. Access said MuGard...
...An Pharmaceuticals Ltd. (Shenzhen, China) an exclusive sublicense to commercialize MuGard in China and Taiwan. MuGard...
...the Netherlands) has rights to MuGard in Europe. Access Pharmaceuticals Inc. (OTCBB:ACCP), Dallas, Texas Product: MuGard...
BioCentury | Jan 9, 2012
Finance

PDUFAs produce yawns

...in 2012. Source:BCIQ:BioCenturyOnlineIntelligence Company Product Indication Event Milestone Access Pharmaceuticals Inc. (OTCBB:ACCP)/ RHEI Pharmaceuticals Inc. MuGard...
Items per page:
1 - 10 of 21